We are bringing a new generation of vaccines to empower people everywhere to live healthy lives.
We are bringing a new generation of vaccines to empower people everywhere to live healthy lives.
A Better Vaccine: IVT PCV-25
Our lead candidate, Pneumococcal Conjugate Vaccine for Paediatric, leverages the Inventprise proprietary Linker Conjugation Platform to result in a longer-lasting vaccine with more coverage and a better immune response.
Proprietary Linker Conjugation Platform
Inventprise’s proprietary scalable conjugation technology based on the Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines.
Proprietary Linker Conjugation Platform
Inventprise’s proprietary scalable conjugation technology based on the Hydrazied-PEG-Hydrazide (Hz-PEG-Hz) linker designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines.
READ MORE
State-of-the-Art, Highly Automated Manufacturing with Capacity to Supply Global Demand.
State-of-the-Art, Highly Automated Manufacturing with Capacity to Supply Global Demand
Recent Inventprise News
PRESS RELEASE Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate The 25 valent pneumococcal …
INVENTPRISE IN THE NEWS Inventprise President & CEO Yves Leurquin Attends 2nd Global Forum on Childhood Pneumonia Yves Leurquin shared the vision and mission of …